KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Equity Average (2016 - 2025)

Sarepta Therapeutics has reported Equity Average over the past 15 years, most recently at $1.2 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 10.48% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, down 10.48%, while the annual FY2025 figure was $1.3 billion, 11.78% up from the prior year.
  • Equity Average for Q4 2025 was $1.2 billion at Sarepta Therapeutics, down from $1.3 billion in the prior quarter.
  • Over five years, Equity Average peaked at $1.4 billion in Q4 2024 and troughed at $407.9 million in Q4 2022.
  • A 5-year average of $872.7 million and a median of $801.8 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: tumbled 53.35% in 2021 and later skyrocketed 99.03% in 2023.
  • Year by year, Equity Average stood at $698.8 million in 2021, then plummeted by 41.63% to $407.9 million in 2022, then soared by 99.03% to $811.8 million in 2023, then soared by 69.29% to $1.4 billion in 2024, then fell by 10.48% to $1.2 billion in 2025.
  • Business Quant data shows Equity Average for SRPT at $1.2 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.3 billion in Q2 2025.